CellWell record HH-591278
Rising Use of Unapproved BPC-157 (“Wolverine Peptide”) and Associated Patient-Reported Outcomes Curated from Clinical Notes
AJ Venkatakrishnan; Adhikaar Marwaha; Christopher Gregg; Gowtham Varma; Matthew Hurchik; Karthik Murugadoss; Santhosh Shivabasappa; Venky Soundararajan
2026
In plain language
Documented use of an unapproved synthetic peptide rose 33-fold from 2020 to 2026 across clinical notes, with most reported improvement, but the authors note these reports cannot establish efficacy.
- Evidence
- Emerging
- Design
- Preprint
Cite this record: https://thecellwell.org/studies/HH-591278
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.